Pierre Marie coined the term ‘acromegaly' in 1886 and linked it to a distinct clinical disease with a characteristic clinical picture. However, Pierre Marie was not the first physician to give a full record of the clinical picture of acromegaly; others had preceded him, like the Dutch physician Johannes Wier. After Marie, pituitary enlargement was noted in almost all patients with acromegaly. Subsequently it was discovered that pituitary hyperfunction caused by a pituitary tumour was indeed the cause of acromegaly. The cause of acromegaly could be further determined after the discovery of growth hormone (GH) and insulin-like growth factor I (IGF-I) and after demonstrating an association with GH hypersecretion and elevated circulating IGF-I. From the beginning of the 20th century, acromegaly could be treated by pituitary surgery and/or radiotherapy. After 1970, medical therapies were introduced that could control acromegaly. First, dopamine agonists were introduced, followed by somatostatin analogues and GH receptor blockers.

Keywords:
Pituitary surgery, Acromegaly, Gigantism, Growth hormone
1.
Marie P: Sur deux cas d'acromégalie; hypertrophie singulière non congénitale des extrémités supérieures, inférieures et céphalique. Rev Med Liège 1886;6:297-333.
2.
de Herder WW: Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886). Pituitary 2009;12:236-244.
3.
Wier (Weyer) J: Medicarum Observationum. Virgo Gygantea ex quartana reddita. Basel, Oporinus, 1567, pp 7-10.
4.
Saucerotte N: Accroissement singulier en grosseur des os d'un homme âgé de 39 ans. Observation communiquée à l'Académie de chirurgie. Mélanges de Chirurgie 1801;2:407-411.
5.
Pearce JM: Nicolas Saucerotte: acromegaly before Pierre Marie. J Hist Neurosci 2006;15:269-275.
6.
Alibert J-LM: Précis théorique et pratique sur les maladies de la peau. Paris, Caille et Ravier, 1822, p 317.
7.
Verga A: Caso singolare de prosopectasia. Reale Istituto Lombardo di Scienze e Lettere Rendiconti Classe di Scienze Matematiche e Naturali 1864;1:111-117.
8.
Danzig J: Doctor protests at greeting card manufacturer making fun of woman with acromegaly. Br Med J 2014;333:936.
9.
de Herder WW, Périé J, Gnodde A: Gigantism and Acromegaly in the 20th Century. Breda, Npn drukkers, 2013.
10.
Lombroso C: Merkwürdiger Fall von allgemeiner Hypertrophie (macrosomia) oder scheinbarer Elephantiasis, beobachtet von Prof. Lombroso, mitgeteilt von Dr. Fränkel. Virchows Arch Pathol Anat Physiol Klin Med 1869;6:253.
11.
Lombroso C: Caso singolare di macrosomia simulante. Giornale Italiano delle Malattie Veneree e delle Malattie della Pelle 1868;02:129-135.
12.
Lombroso C: Caso singolare di macrosomia. Annali Universali di Medicina 1872;227:505.
13.
Henrot H: Notes de clinique médicale. Des lésions anatomiques et de la nature du myxoedéme. Reims, Matot-Braineneuvième année, 1882, pp 112-122.
14.
Henrot H: Hypertrophie générale progressive. Notes de clinique médicale. Reims, 1877, p 56.
15.
Brigidi V: Studii anatomopatologica sopra un uomo divenuto stranamente deforme per chronica infirmita. Societe medico-fisica Fiorentina, 1877.
16.
Souza-Leite JD: De l'acromégalie, maladie de Marie; thèse, Paris, 1890.
17.
Marie P, Marinesco G: Sur l'anatomie pathologique de l'acromégalie. Arch Med Exp Anat Pathol 1891;3:539-564.
18.
Marie P: L'acromégalie. Nouvelle Iconographie de la Salpétrière 1888;I:173, 229.
19.
Marie P: L'acromégalie. Nouvelle Iconographie de la Salpétrière 1889;II:45, 139, 188, 224, 327.
20.
Marie P: Acromegaly. Brain 1890;12:59.
21.
Marie P: Troisième leçon: Déformations thoraciques dans quelques affections médicales (Suite). B. Déformations thoraciques acquises. Acromégalie. Leçons de Clinique Médicale. Paris, Masson, 1896.
22.
McAlister NH: John Hunter and the Irish giant. Can Med Assoc J 1974;111:256-257.
23.
Fulton JF: Harvey Cushing. A biography. Springfield, Charles C Thomas, 1946.
24.
Cushing H: Neurohypophysial mechanisms from a clinical standpoint. Lancet 1930;ii:119-127, 175-184.
25.
Bergland RM: New information concerning the Irish giant. J Neurosurg 1965;23:265-269.
26.
Pearce JM: Harvey William Cushing (1869-1939). J Neurol 2000;247:397-398.
27.
Keith A: An inquiry into the nature of the skeletal changes in acromegaly. Lancet 1911;i:993-1002.
28.
Minkowski O: Über einem Fall von Akromegalie. Klin Wochenschr 1887;21:371-374.
29.
Massolongo R: Hyperfonction de la glande pituitaire et acromégalie; gigantisme et acromégalie. Rev Neurol 1895;3:225.
30.
Benda C: Die microscopischen Befunde bei vier Fällen von Akromegalie. Dtsch Med Wochenschr 1901;27:537-564.
31.
Benda C: Beiträge zur normalen und pathologischen Histologie der menschlichen Hypophysis cerebri. Klin Wochenschr 1900;1205-1210.
32.
Tamburini A: Beitrag zur Pathogenese der Akromegalie. Zentralbl Nervenheilk Psychiatr 1894;17:625.
33.
Hutchinson W: The pituitary gland as a factor in acromegaly and giantism. NY Med J 1898;67:341-344, 450-453.
34.
Hutchinson W: The pituitary gland as a factor in acromegaly and giantism. NY Med J 1898;72:89-100, 133.
35.
Guinon G: De l'acromégalie. Gazette Hopitaux Paris 1889;62:1161.
36.
Fritsche CF, Klebs E: Ein Beitrag zur Pathologie des Riesenwuchses. Klinische und pathologischanatomische Untersuchungen. Leipzig, Vogel FCW, 1884.
37.
Langer K: Wachstum des menschlichen Skeletts, mit Bezug auf den Riesen. Denkschr der Kais Akad der Wissensch zu Wien Math Naturw 1872;XXXI Bd. II. Abth (pamphlet).
38.
Sternberg M: Beiträge zur Kenntnis der Akromegalie. Z Klin Med 1894;27:86.
39.
Sternberg M: Die Akromegalie; in Nothnagel CWH (ed): Nothnagel's Encyclopedia. Vienna, 1897.
40.
Cunningham DJ: The skeleton of the Irish giant Cornelius Magrath. Transactions of the Royal Irish Academy 1891;29:553.
41.
Cunningham DJ: Cornelius Magrath, the Irish Giant. Man 1903;3:49-50.
42.
Cunningham DJ: The skull and some of the other bones of the skeleton of Cornelius Magrath, the Irish giant. J Anthropol Inst Great Britain Ireland 1892;21:40-41.
43.
Dana C: On acromegaly and gigantism, with unilateral facial hypertrophy. J Nerv Ment Dis 1893;18:725-738.
44.
Hutchinson W: A case of acromegaly in a giantess. Am J Med Sci 1895;CX:190-201.
45.
Brissaud E, Meige H: Gigantisme et acromégalie. J Med Chir Prat 1895;66:49.
46.
Launois P-E, Roy P: Études biologiques sur les géants. Paris, Masson et Cie, 1904.
47.
Pearce JM: Pituitary tumours and acromegaly (Pierre Marie's disease). J Neurol Neurosurg Psychiatry 2002;73:394.
48.
Sheaves R: A history of acromegaly. Pituitary 1999;2:7-28.
49.
Chahal HS, Stals K, Unterlander M, et al: AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med 2011;364:43-50.
50.
de Herder WW: Acromegalic gigantism, physicians and body snatching. Past or present? Pituitary 2012;15:312-318.
51.
Vierimaa O, Georgitsi M, Lehtonen R, et al: Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006;312:1228-1230.
52.
Daly AF, Tichomirowa MA, Petrossians P, et al: Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 2010;95:E373-E383.
53.
Trivellin G, Daly AF, Faucz FR, et al: Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med 2014;371:2363-2374.
54.
Cushing H: The Pituitary Body and its Disorders. Clinical States Produced by Disorders of the Hypophysis Cerebri. Philadelphia, JB Lippincott, 1912.
55.
Vassale G, Sacchi E: Sulla distruzione della ghiandola pituitaria: richerche sperimentali. Riv Sper Freniatr Med Leg Alien Ment 1892;18:525-561.
56.
Vassale G, Sacchi E: Ulteriori esperienze sulla ghiandola pituitaria. Riv Sper Freniatr Med Leg Alien Ment 1894;20:83-88.
57.
Paulesco NC: L'hypophyse du cerveau. J Physiol Pathol Gen 1907;9:441-456.
58.
Aschner B: Über die Funktion der Hypophyse. Pflugers Arch Gesamte Physiol Menschen Tiere 1912;146:1-46.
59.
Aschner B: Demonstration von Hunden nach Exstirpation der Hypophyse (kurze Mitteilung). Wien Klin Wochenschr 1909;22:1730-1732.
60.
Aschner B: Demonstration von Hunden nach Exstirpation der Hypophyse (kurze Mitteilung). Wien Klin Wochenschr 1910;23:572.
61.
Aschner B: Über die Folgeerscheinungen nach Exstirpation der Hypophyse. Verh Dtsch Ges Chir 1910;39:46-49.
62.
Handelsmann J, Horsley V: Preliminary note on experimental investigations on the pituitary body. Br Med J 1911;1150-1151.
63.
Caton R, Paul FT: Notes on a case of acromegaly treated by operation. Br Med J 1893;2:1421-1423.
64.
Horsley V: Address in surgery on the technic of operation on the central nervous system. Br Med J 1906;2:411-423.
65.
Schloffer H: Erfolgreiche Operationen eines Hypophysentumors auf nasalem Wage. Wien Klin Wochenschr 1907;20:621-624.
66.
Hochenegg J: Operat geheilte Akromegalie bei Hypophysentumor. Verh Dtsch Ges Chir 1908;37:80-85.
67.
Hirsch O: Endonasal method of removal of hypohyseal tumors. JAMA 1910;5:772-774.
68.
Tucker HM, Hahn JF: Transnasal, transeptal sphenoidal approach to hypophysectomy. Laryngoscope 1982;92:55-57.
69.
Hardy J: Transsphenoidal hypophysectomy. J Neurosurg 1971;34:582-594.
70.
Mislow JM, Golby AJ, Black PM: Origins of intraoperative MRI. Magn Reson Imaging Clin N Am 2010;18:1-10.
71.
Fahlbusch R, Thapar K: New developments in pituitary surgical techniques. Baillieres Best Pract Res Clin Endocrinol Metab 1999;13:471-484.
72.
Béclère A: Le traitement médical des tumeurs hypophysaires, du gigantisme et de l'acromégalie par la radiothérapie. Bull Mem Soc Med Hop Paris 1909;27:274.
73.
Gramenga A: Un cas d'acromegalie traité par la radiothérapie. Rev Neurol 1909;17:15-17.
74.
Kjellberg RN, Shintani A, Frantz AG, Kliman B: Proton-beam therapy in acromegaly. N Engl J Med 1968;689-695.
75.
Pollock BE, Jacob JT, Brown PD, Nippoldt TB: Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 2007;106:833-838.
76.
Li CH, Evans HM, Simpson ME: Isolation and properties of the anterior hypophyseal growth hormone. J Biol Chem 1945;159:353-366.
77.
Harris GW: The hypothalamus and endocrine glands. Br Med Bull 1950;6:345-350.
78.
Guillemin R: Peptides in the brain. The new endocrinology of the neuron. Nobel Lecture, 8 December, 1977. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1977/guillemin-lecture.pdf. 1977.
79.
Schally AV: Aspects of Hypothalamic Regulation of the Pituitary Gland with Major Emphasis on Its Implications for the Control of Reproductive Processes. Nobel Lecture, December 8, 1977. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1977/schally-lecture.pdf. 1977.
80.
Yalow RS: Radioimmunoassay: A Probe for Fine Structure of Biological Systems. Nobel Lecture, December 8, 1977. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1977/yalow-lecture.pdf. 1977.
81.
Salmon WD Jr, Daughaday WH: A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957;49:825-836.
82.
Daughaday WH, Hall K, Raben MS, Salmon WD Jr, Van den Brande JL, Van Wyk JJ: Somatomedin: proposed designation for sulphation factor. Nature 1972;235:107.
83.
Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE: Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979;301:1138-1142.
84.
Froesch ER, Buergi H, Ramseier EB, Bally P, Labhart A: Antibody-suppressible and nonsuppressible insulin-like activities in human serum and their physiologic significance. An insulin assay with adipose tissue of increased precision and specificity. J Clin Invest 1963;42:1816-1834.
85.
Klapper DG, Svoboda ME, Van Wyk JJ: Sequence analysis of somatomedin-C: confirmation of identity with insulin-like growth factor I. Endocrinology 1983;112:2215-2217.
86.
Daughaday WH, Hall K, Salmon WD Jr, Van den Brande JL, Van Wyk JJ: On the nomenclature of the somatomedins and insulin-like growth factors. J Clin Endocrinol Metab 1987;65:1075-1076.
87.
Baxter RC: Circulating binding proteins for the insulinlike growth factors. Trends Endocrinol Metab 1993;4:91-96.
88.
Coulson VJ, Wass JA, Abdulla AF, Cotterill AM, Holly JM: Insulin-like growth factor binding proteins (IGFBPs) in acromegaly. Growth Regul 1991;1:119-124.
89.
Krulich L, Dhariwal AP, McCann SM: Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968;83:783-790.
90.
Colao A, Bronstein MD, Freda P, et al: Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 2014;99:791-799.
91.
Besser GM, Wass JA, Thorner MO: Acromegaly - results of long term treatment with bromocriptine. Acta Endocrinol Suppl (Copenh) 1978;216:187-198.
92.
Lombardi G, Colao A, Ferone D, et al: CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol 1995;132:559-564.
93.
Abs R, Verhelst J, Maiter D, et al: Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-378.
94.
Brazeau P, Vale W, Burgus R, et al: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-79.
95.
Vale WF, Rivier JF, Ling NF, Brown M: Biologic and immunologic activities and applications of somatostatin analogs. Metabolism 1978;9(suppl 1):1391-1401.
96.
Bauer W, Briner U, Doepfner W, et al: SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-1140.
97.
Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ: Octreotide. N Engl J Med 1996;334:246-254.
98.
Kopchick JJ, Okada S: Growth hormone receptor antagonists: discovery and potential uses. Growth Horm IGF Res 2001;11(suppl A):S103-S109.
99.
Trainer PJ, Drake WM, Katznelson L, et al: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-1177.
100.
van der Lely AJ, Hutson RK, Trainer PJ, et al: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-1759.
101.
Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ: Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007;92:4598-4601.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.